This One Factor Could Cause 10X Genomics Inc (TXG) Stock to Tumble
Leerink Partners has recently reduced 10X Genomics Inc (TXG) stock to Market Perform rating, as announced on February 13, 2025, according to Finviz. Earlier, on September 3, 2024, Leerink Partners had initiated the stock to Outperform, setting a price target of $35. Jefferies also raised Buy rating with a price target of $24. Additionally, JP […]
Could 10X Genomics Inc (TXG) Stock Take a Sudden Turn for the Worse? Here’s What’s at Stake
Leerink Partners has recently reduced 10X Genomics Inc (TXG) stock to Market Perform rating, as announced on February 13, 2025, according to Finviz. Earlier, on September 3, 2024, Leerink Partners had initiated the stock to Outperform, setting a price target of $35. Jefferies also raised Buy rating with a price target of $24. Additionally, JP […]
Why 10X Genomics Inc (TXG) Stock Could Be the Next Market-Loser
Leerink Partners has recently reduced 10X Genomics Inc (TXG) stock to Market Perform rating, as announced on February 13, 2025, according to Finviz. Earlier, on September 3, 2024, Leerink Partners had initiated the stock to Outperform, setting a price target of $35. Jefferies also raised Buy rating with a price target of $24. Additionally, JP […]
This 10X Genomics Inc (TXG) Stock Prediction Could Blow Your Mind
Leerink Partners has recently reduced 10X Genomics Inc (TXG) stock to Market Perform rating, as announced on February 13, 2025, according to Finviz. Earlier, on September 3, 2024, Leerink Partners had initiated the stock to Outperform, setting a price target of $35. Jefferies also raised Buy rating with a price target of $24. Additionally, JP […]
Las Vegas Sands Corp. (LVS) Stock: Is the Wild Ride Taking It Higher?
Leerink Partners has recently initiated 10X Genomics Inc (TXG) stock to Outperform rating, as announced on September 3, 2024, according to Finviz. Earlier, on July 22, 2024, Jefferies had raised the stock from a Hold to Buy, setting a price target of $24. JP Morgan also reduced Neutral rating with a price target of $20. […]
Are Bioatla Inc (BCAB) Stock’s Days of Explosive Growth Over?
Leerink Partners has recently initiated 10X Genomics Inc (TXG) stock to Outperform rating, as announced on September 3, 2024, according to Finviz. Earlier, on July 22, 2024, Jefferies had raised the stock from a Hold to Buy, setting a price target of $24. JP Morgan also reduced Neutral rating with a price target of $20. […]
Why Did 10X Genomics Inc (TXG) Stock See -17.82% Plunge in the Last 90 Days?
Leerink Partners has recently initiated 10X Genomics Inc (TXG) stock to Outperform rating, as announced on September 3, 2024, according to Finviz. Earlier, on July 22, 2024, Jefferies had raised the stock from a Hold to Buy, setting a price target of $24. JP Morgan also reduced Neutral rating with a price target of $20. […]
10X Genomics Inc (TXG) Stock: A Deeper Look at Its True Potential
Leerink Partners has recently initiated 10X Genomics Inc (TXG) stock to Outperform rating, as announced on September 3, 2024, according to Finviz. Earlier, on July 22, 2024, Jefferies had raised the stock from a Hold to Buy, setting a price target of $24. JP Morgan also reduced Neutral rating with a price target of $20. […]
Why Did 10X Genomics Inc (TXG) Stock Surge 1.21% Last Week?
Leerink Partners has recently initiated 10X Genomics Inc (TXG) stock to Outperform rating, as announced on September 3, 2024, according to Finviz. Earlier, on July 22, 2024, Jefferies had raised the stock from a Hold to Buy, setting a price target of $24. JP Morgan also reduced Neutral rating with a price target of $20. […]
10X Genomics Inc (TXG) Reported a -28.30% Operating Margin Last Year—What’s the Real Story?
Leerink Partners has recently initiated 10X Genomics Inc (TXG) stock to Outperform rating, as announced on September 3, 2024, according to Finviz. Earlier, on July 22, 2024, Jefferies had raised the stock from a Hold to Buy, setting a price target of $24. JP Morgan also reduced Neutral rating with a price target of $20. […]
